Meaverin (Mepivacaine Hydrochloride)

Mepivacaine Hydrochloride blocks voltage‑gated sodium channels on neuronal membranes, preventing the initiation and propagation of action potentials. This reversible inhibition stops nerve impulse transmission, producing a localized loss of sensation without affecting consciousness.

The appropriate dose of Meaverin is determined by the prescribing clinician based on the specific procedure, patient weight, and clinical context. Dosage recommendations are provided in the product labeling and must be individualized for each patient.

Safety data for Mepivacaine Hydrochloride in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and under close medical supervision.

To order Meaverin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mepivacaine Hydrochloride offers a rapid onset similar to lidocaine but with a slightly longer duration of action and less vasodilatory effect, often reducing the need for a vasoconstrictor. It is an amide‑type anesthetic, providing reliable nerve block for short‑ to medium‑duration procedures.

Store Meaverin at ambient temperature, preferably below 25 °C, in its original packaging. Protect the solution from direct light, moisture and extreme temperature fluctuations. Ensure the container is sealed when not in use to maintain sterility.

Meaverin is supplied as a sterile injectable solution and can be administered via epidural, intradermal or intravenous routes. The injection technique follows standard aseptic procedures, and the volume injected is determined by the prescriber according to the intended anesthetic effect.

Serious adverse events, though rare, include cardiac arrhythmias, seizures, and methemoglobinemia. Patients should be monitored for signs of cardiovascular instability, central nervous system excitation, or abnormal oxygen saturation, and immediate medical intervention should be available.

Meaverin should be avoided in individuals with a known hypersensitivity to Mepivacaine, other amide‑type local anesthetics, or any component of the formulation. It is also contraindicated in patients with severe cardiac conduction disorders or uncontrolled arrhythmias unless the benefits outweigh the risks.